SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-088185
Filing Date
2023-03-31
Accepted
2023-03-31 16:37:02
Documents
15
Period of Report
2023-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d436260d8k.htm   iXBRL 8-K 39411
2 EX-99.1 d436260dex991.htm EX-99.1 10519
7 GRAPHIC g436260g0331023958527.jpg GRAPHIC 3003
  Complete submission text file 0001193125-23-088185.txt   224737

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mgta-20230331.xsd EX-101.SCH 3883
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mgta-20230331_def.xml EX-101.DEF 14080
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mgta-20230331_lab.xml EX-101.LAB 23351
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mgta-20230331_pre.xml EX-101.PRE 15113
9 EXTRACTED XBRL INSTANCE DOCUMENT d436260d8k_htm.xml XML 5283
Mailing Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139
Business Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Magenta Therapeutics, Inc. (Filer) CIK: 0001690585 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38541 | Film No.: 23788486
SIC: 2834 Pharmaceutical Preparations